Last reviewed · How we verify
SY-5933
At a glance
| Generic name | SY-5933 |
|---|---|
| Also known as | SY-5933 tablet |
| Sponsor | Shouyao Holdings (Beijing) Co. LTD |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of SY-5933 Plus CT-707 in Advanced Solid Tumors With KRAS p.G12C Mutation (PHASE1, PHASE2)
- A Study of SY-5933 in Patients With Advanced Solid Tumors Harboring the KRAS p.G12C Mutation (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SY-5933 CI brief — competitive landscape report
- SY-5933 updates RSS · CI watch RSS
- Shouyao Holdings (Beijing) Co. LTD portfolio CI